Lumida
/FATE
⌘K
Fate Therapeutics Inc

Fate Therapeutics Inc

FATE
$2.31USD-0.86%-0.02 today

MARKET CAP

276.8M

P/E (TTM)

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$1
$3

AI Summary

Stalk
Buy NowMedium

Stock is in a Stage 2 uptrend medium-term bullish environment, showing a pullback into rising EMAs that have held support, offering a timely buy opportunity despite a Bullish Exhaustion pattern that signals possible short-term fatigue.

  • RECLAIM-LN Phase 2 trial for FT819 in SLE launched; first patient dosed.
  • $153.8M cash as of June 30 2026 funds operations into 2028.
  • Q2 2026 net loss $30M and EPS –$0.25 reflect ongoing losses.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$55.8M$96.3M$63.5M$13.6M$6.6M
YoY %+77.7%+72.4%-34.0%-78.5%-51.2%
P / Sales99.3x10.2x5.7x13.8x17.6x
EV / Sales101.2x11.9x7.2x20.0x27.3x
Gross Profit, Adj.$55.8M$96.3M$63.5M$13.6M$6.6M
YoY %+77.7%+72.4%-34.0%-78.5%-51.2%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit101.2x11.9x7.2x20.0x27.3x
EBITDA, Adj.$-207.1M$-292.0M$-165.0M$-176.6M$-134.8M
YoY %-70.0%-40.9%+43.5%-7.0%+23.7%
Margin %-370.9%-303.2%-259.8%-1295.4%-2028.3%
EV / EBITDA-27.3x-3.9x-2.8x-1.5x-1.3x
EBIT$-217.0M$-308.4M$-190.5M$-210.3M$-147.7M
YoY %-69.4%-42.1%+38.2%-10.4%+29.8%
Margin %-388.6%-320.2%-299.9%-1542.6%-2222.4%
EV / EBIT-26.1x-3.7x-2.4x-1.3x-1.2x
Net Income$-212.2M$-281.7M$-160.9M$-186.3M$-136.3M
YoY %-22.4%-32.8%+42.9%-15.7%+26.8%
Net Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
EPS (GAAP)-$2.24-$2.91-$1.64-$1.64-$1.15
YoY %-6.7%-29.9%+43.6%+29.9%